Inhibitory action of newly synthesised 4-(2-(2-substituted-thio-4-oxoquinazolin-3(4H)-yl)ethyl)benzenesulfonamides compounds 2-13 against human carbonic anhydrase (CA, EC 4.2.1.1) (hCA) isoforms I, II, IX, and XII, was evaluated. hCA I was efficiently inhibited by compounds 2-13 with inhibition constants (K I s) ranging from 57.8-740.2 nM. Compounds 2, 3, 4, and 12 showed inhibitory action against hCA II with K I s between 6.4 and 14.2 nM. CA IX exhibited significant sensitivity to inhibition by derivatives 2-13 with K I values ranging from 7.1 to 93.6 nM. Compounds 2, 3, 4, 8, 9, and 12 also exerted potent inhibitory action against hCA XII (K I s ranging from 3.1 to 20.2 nM). Molecular docking studies for the most potent compounds 2 and 3 were conducted to exhibit the binding mode towards hCA isoforms as a promising step for SAR analyses which showed similar interaction with co-crystallized ligands. As such, a subset of these mercaptoquinazolin-4(3H)-one compounds represented interesting leads for developing new efficient and selective carbonic anhydrase inhibitors (CAIs) for the management of a variety of diseases including glaucoma, epilepsy, arthritis and cancer.
Introduction
Carbonic anhydrases (CAs; EC 4.2.1.1) constitute the superfamily of metalloenzymes catalysing the CO 2 hydration/dehydration reaction. CAs are classified into eight genetically distinct families, named a-, b-, c-, d-, f-, g-, Õ-, and i-CAs 1,2 . 15 a-class isoenzymes have been detected in humans (h) and are sorted into four different subsets depending on their subcellular localisation: CA I, II, III, VII, VIII, X, XI, XIII are cytosolic proteins, CA VA and VB are present in the mitochondrial matrix, CA VI is a secreted enzyme, CA IV is a glycosylphosphatidylinositol (GPI)-anchored protein and CA IX, XII, and XIV are trans-membrane isoforms [1] [2] [3] . hCAs are spread in the human body and are implicated in a plethora of essential physiological processes. As a result, critical pathological conditions might occur upon their dysregulated expression and/or abnormal activity 2 . CA II is the most physiologically relevant isoform and is implicated in disorders such as cerebral oedema, glaucoma (such as CA XII), and epilepsy. It is conversely off-target like CA I, when targeting tumours where CA IX and XII are overexpressed and represent validated targets to combat the growth of both primary tumours and metastasis 4 . Significant similarity exists amongst the active site's architecture of hCAs making it difficult to produce inhibitors that exhibit net isoform-specificity in action and do not induce side effects as a consequence of CA inhibition 1 . Aromatic sulphonamides constitute the main subset of CAIs developed to date and have been clinically used for decades as diuretic, antiglaucoma, antiobesity, and antiepilepsy medications. The ureidobenzenesulfonamide SLC-0111 ( Figure 1 ), a selective CA IX/XII inhibitor, is currently in Phase II/b clinical trials for the therapy of solid, metastatic tumours [2] [3] [4] [5] [6] . A wealth of sulphonamide derivatives have been reported as CAIs 5, [7] [8] [9] [10] [11] [12] [13] [14] [15] [16] [17] [18] [19] , COX-2 inhibitors, or antitumor 13, 15, [20] [21] [22] . The quinazolinone scaffold is also widely used in medicinal chemistry [23] [24] [25] [26] [27] [28] [29] [30] [31] [32] [33] [34] [35] [36] [37] [38] [39] , such as COX-1/2 inhibitors 23, 24 and antitumor [25] [26] [27] [28] [29] [37] [38] [39] . 4-(2-(4-Oxo-2-thioxo-1,4-dihydroquinazolin-3(2H)yl)ethyl)benzenesulfonamide (1, Figure 1 ) showed effective inhibitory activity against a subset of hCA isoforms with subnanomolar inhibition constants 40 . Likewise, a series of 2-((3-benzyl-4oxo-3,4-dihydroquinazolin-2-yl)thio)-N-(4-sulfamoylphenethyl)amides (A, Figure 1 ) showed nanomolar inhibitory action against a panel of hCAs 39 . Various quinazolin-4-yl-aminobenzenesulfonamide, quinazolin-4-yl-oxy-benzenesulfonamide derivatives (B, Figure 1 ) and 3-(6-iodo-4-oxo-2-thioxo-1,4-dihydroquinazolin-3(2H)-yl)benzenesulfonamide, 3-(2-mercapto-7-fluoro-4(3H)quinazolinon-3-yl)-benzenesulfonamide (C, Figure 1 ) were reported to exert potent inhibitory effect against CA I, II, IX and XII 41, 42 . As observed from SAR analysis of the reported C derivatives ( Figure 1 ), it is thought to add an ethyl linker between sulphonamide part and quinazoline scaffold and alkylation of free SH group to increase the lipophilicity as activity parameter in CA enzyme. Therefore, we report the synthesis of a new series of 4-(2-(2-(substituted-thio)-4-oxoquinazolin-3(4H)-yl)ethyl)benzenesulfonamide compounds (2-13, Figure 1 ) and evaluated their inhibitory action against four pharmacologically relevant hCA isoforms, I, II, IX, and XII.
Materials and methods

Chemistry
Melting points were recorded on a Barnstead 9100 electrothermal melting point apparatus (UK). IR spectra (KBr) were recorded on a FT-IR Perkin-Elmer spectrometer (Perkin Elmer Inc., Waltham, MA). Nuclear magnetic resonance ( 1 H and 13 C NMR) spectra were recorded with Bruker 500 or 700 MHz spectrometers (Zurich, Switzerland) using DMSO-d 6 as the solvent. Micro-analytical data (C, H, and N) were obtained using a Perkin-Elmer 240 analyser (Perkin Elmer Inc., MA) and agreed with the proposed structures within ±0.4% of the theoretical values. Mass spectra were recorded on a Varian TQ 320 GC/MS/MS mass spectrometer (Varian, Palo Alto, CA).
4-(2-(4-Oxo-2-thioxo-1,4-dihydroquinazolin-3(2H)-yl)ethyl)benzenesulfonamide compound 1 was prepared by heating anthranilic acid with 4-(2-isothiocyanatoethyl)benzenesulfonamide in ethanol in the presence of triethylamine 40 . (1) (1 mmol, 361 mg), appropriate halide (1 mmol) and potassium carbonate (3 mmol, 415 mg) in 7 ml acetone were stirred at room temperature for 8-13 h. The reaction mixture was filtered and the prepared solid was washed with water and dried. 
CA inhibition
The hCA I, II, IX, and XII isoenzyme inhibition assay was performed according to the reported method using SX.18 MV-R stopped-flow instrument (Applied Photophysics, Oxford, UK) [43] [44] [45] . All CA isoforms were recombinant isoforms obtained in-house, as reported earlier 46,47 .
Molecular docking method
Molecular docking was carried out according to the previously reported methods 24 
Results and discussion
3.1. Chemistry 4-(2-(4-Oxo-2-thioxo-1,4-dihydroquinazolin-3(2H)-yl)ethyl)benzenesulfonamide (1) was obtained through the reaction between anthranilic acid, 4-(2-isothiocyanatoethyl)benzenesulfonamide and triethylamine in ethanol 40, 54 (Scheme 1). Its yield was 93%. Stirring of compound 1 with potassium carbonate in acetone and different alkyl-halides or aralkyl-halides produced the corresponding 4-(2-(2-(substituted-thio)-4-oxoquinazolin-3(4H)-yl)ethyl)benzenesulfonamides 2-13 with 90-95% yield. Various spectral analyses were performed to confirm the structures of compounds 2-13. The formation of target compounds was assessed by the disappearance of thioamide proton (NH-C ¼ S) at 13.03 ppm in 1 H NMR and thione moiety (NH-C ¼ S) at 175.29 ppm in the 13 C NMR spectra, together with presence of the new thio-substituted moieties (S-R), that were confirmed by 1 H NMR and 13 C NMR spectra.
CA inhibitory activity
The CAI activity of newly produced 4-(2-(2-(substituted-thio)-4oxoquinazolin-3(4H)-yl)ethyl)benzenesulfonamides 2-13 against hCA I, II, IV, and IX isoforms was measured by a Stopped-Flow kinetic assay 48 and compared to acetazolamide (AAZ), a standard sulphonamide inhibitor (Table 1, Figure 2 ). The hCA I was effectively inhibited by compounds 2-13 with inhibition constant (K I ) values in the range of 57.8-740.2 nM, (AAZ: K I , 250.0 nM). Compounds 2, 3, 4, and 12 showed to be potent hCA II inhibitors, with K I values between 6.4 and 14.2 nM, which were greater than or nearly identical to that of AAZ (K I , 12.0 nM). Compounds 7-11 and 13 showed modest hCA II inhibitory activity with K I s ranging between 66. 5 Figure 2 ).
The following structure-activity relationship (SAR) can be drawn on the basis of the inhibition data shown in Table 1 . III. SAR analysis for hCA IX inhibition indicated that: (1) 2-(aliphatic-thio)quinazolin-4(3H)-one such as compounds 2-4 (K I values ranging between 7.1 and 12.6 nM) were more active than the corresponding 2-(benzylthio)quinazolin-4(3H)-one 5-11, 4-(2-(4-oxo-2-((2-(piperidin-1-yl)ethyl)thio)quinazolin-3(4H)-yl)ethyl)benzenesulfonamide (12) produced compound 13 with a significant decrease in CAI activity (K I , 71.4 nM).
Molecular docking studies
The docking simulations between the hCAs targets, and the most active compounds such as 2 and 3, as well as least active compound such as 6 compared with the prototype 1 lead compound were performed using MOE Suite 53 .
Docking of compounds 2, 3, and 6 with hCA isoenzymes
The most active methyl derivative 2 was docked with the binding pockets of the hCA isoforms II and XII, utilising the different protein crystal structures; 5ULN and 1JD0 downloaded from Protein Data Bank store 55, 56 . As shown in Figure 3 , and Table 2 , the results suggested that the compound 2 displayed similar patterns to the co-crystallized ligands. Firstly, the docking pose of compound 2 in the complex with isoform II formed bidentate chelate with SO 2 NH 2 fragment with zinc metal at a distance range of 2.45-2.01 Å. The sulphonyl part was stabilised by three strong hydrogen bonds through the residues, Thr199 and Leu198 at average bond distance of 2.35-2.22 Å. Moreover, the carbonyl moiety of 4(3H)quinazolinone was stabilised by direct and indirect hydrogen bonding between water and polar residues Gln92 and Asn67 at distance of 2.25 Å as co-crystallized inhibitor S-atom does. In addition, hydrophobic interactions were experienced with methylthioether fragment through Phe131 residue. Secondly, the docking poses of compound 2 in the complex with isoform XII exhibited interactions like the co-crystallized inhibitor especially the SO 2 NH 2 part with Zinc metal and stabilising Thr199 and Thr200 residues. In addition, hydrophobic interactions were experienced with methylthioether fragment through Leu141 residue. The compound 3 was docked with the binding pockets in the hCA isoforms I and IX, utilising the different protein crystal structures; 4WR7 and 5FL4 downloaded from Protein Data Bank store 57, 58 . As shown in Figure 4 and Table 2 , the results suggested that the compound 3 interacted with both active sites in a similar fashion to the co-crystallized ligands in the pockets. Firstly, the docking pose of compound 3 in the complex with isoform I, consisted of a long, narrow tunnel, leading to a cavity that contained the catalytic Zn 2þ ion chelated with SO 2 NH 2 fragment (2.45-2.01 Å) and a sulphonyl part stabilised by two strong hydrogen bonds through the residues, Thr199 and His200 (2.38-2.41 Å). Moreover, different hydrophobic aromatic interactions were also formed with ethylthioether, phenethyl, and 4(3H)quinazolinone moieties through pockets of Leu131, Leu198, Pro202, Leu141, Trp209, Ala135, and Ala132 residues. Secondly, the docking pose of compound 3 in the complex with isoform IX, revealed that the cavity contained the catalytic Zn 2þ ion forming bidentate chelate with SO 2 NH 2 fragment (2.32-2.12 Å) and the sulphonyl part was stabilised by three hydrogen bonds through the residues, Thr200, His96 and His94 (2.44-1.99 Å). Different hydrophobic aromatic interactions were formed with ethylthioether, phenethyl, and 4(3H)quinazolinone moieties through pockets of Val130, Leu134, and Leu91 residues. The 4(3H)quinazolinone was modulated through molecules of H 2 O in the pocket by polar interactions. In addition, the aryl moiety of benzene sulphonamide formed a H 2 Omediated p-p interactions with certain aromatic amino acids. Thr201 might also play an important role in increasing their binding affinity for the enzyme. In addition, the lease active compound 6 was placed in the hCA I binding cavity ( Figure 5, right panel) and results showed that certain factors affecting the incorrect placement like the insertion of S-bromophenyl ring among polar Gln92 and Asn69 residues and disorienting of planer quinazolinone to Leu131 residue. Moreover, the docking of the least active compound 6 into the hCA-II pocket ( Figure 5, left panel) revealed the intolerance of S side chain bromophenyl moiety into the His119 polar part leading to protrusion out of the pocket and so appeared incompatible with pocket residue that makes it low active.
However, the lead compound 1 was docked into the pockets of hCA II and XII ( Figure 6 , Table 2 ) for comparing its behaviour that showed the loss of SH role in the interactions compared to the potent active 2 and 3 derivatives. These overall docking findings proved that the S-alkylated derivatives exhibited good binding interactions better than the lead compound 1.
Conclusions
A new series of 4-(2-(2-substituted-thio-4-oxoquinazolin-3(4H)-yl)ethyl)benzenesulfonamide derivatives 2-13 were synthesised and assessed in vitro for CA inhibition in comparison to AAZ as reference drug. 4-(2-(2-Aliphatic-thio-4-oxoquinazolin-3(4H)-yl)ethyl)benzenesulfonamide derivatives 2-4 showed efficient inhibitory activity against hCA I, hCA II, h IX and hCA XII with K I values ranging between 57.8-85.5, 6.4-13.5, 7.1-12.6, and 3.1-8.6 nM, respectively, which were better or had the same activity as AAZ as Val130, Leu134 Hydrophobic a The data reported in the table were extracted from MOE programme showing the corresponding amino acid residues in enzyme pocket, corresponding fragment of ligands, interaction distances, types of interaction, and their binding energy to prototype 1 and selected active compounds. (13) but lower than 4-(2-(4-Oxo-2-thioxo-1,4-dihydroquinazolin-3(2H)yl)ethyl)benzenesulfonamide (1) as parent compound. Molecular docking studies for compounds 2 and 3 were done and exhibited specific binding modes for hCA isoforms as comparable interaction with lead compound 1.
